In a newly come survey of 261 CEOs...

In a newly come survey of 261 CEOs and licensing executives of biotech companies, 84 percent acknowledged that they face common or more of the following challenges:
* The ability to identify candidates
* The competition for attractive commutes
* Overexposure of US-based licensing opportunities that drive up headline values
Large pharma companies that were historically vain-glorious of their protective R&D "not invented here" mentality have disentangleed impressive and effective licensing organizations. for a like reason it's no surprise that in 2003 more than 24 percent of